Skip to Content
Find More Like This
Return to Search

Structure-based receptor MIMICS targeted against bacterial superantigen toxins

United States Patent

August 18, 2009
View the Complete Patent at the US Patent & Trademark Office
Los Alamos National Laboratory - Visit the Technology Transfer Division Website
The invention provides therapeutic compositions useful in the treatment of bacterial superantigen mediated conditions, such as Toxic Shock Syndrome. The compositions comprise genetically engineered bifunctional polypeptides containing a specific T-cell receptor binding domain and a specific MHC class II receptor binding domain, each targeting non-overlapping epitopes on a superantigen molecule against which they are designed. The anti-superantigen "receptor mimetics" or "chimeras" are rationally designed to recreate the modality of superantigen binding directly to both the TCR and the MHC-II receptor, and are capable of acting as decoys for superantigen binding, effectively out-competing the host T-cell and MHC-II receptors, the natural host receptors.
Gupta; Goutam (Santa Fe, NM), Hong-Geller; Elizabeth (Los Alamos, NM), Shiflett; Patrick R. (Los Alamos, NM), Lehnert; Nancy M. (Albuquerque, NM)
Los Alamos National Security, LLC (Los Alamos, NM)
10/ 746,959
December 24, 2003
STATEMENT REGARDING GOVERNMENT RIGHTS This invention was made with government support under grant number DE-FG02-98ER62647 from the United States Department of Energy and Contract No. W-7405-ENG-36 awarded by the United States Department of Energy to The Regents of The University of California. The government has certain rights in this invention.